A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs Safinamide (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Sponsors Zambon SpA
- 12 Sep 2019 According to a Newron Pharmaceuticals media release, the company expected to start this trial in H2 2019.
- 14 Jun 2019 Status changed from planning to not yet recruiting.
- 05 Mar 2019 According to the Newron Pharmaceuticals media release, this trial is anticipate to start in H1 2019.